Therefore, the baseline model (Model 1) that was used to assess the benefit of adding urine ALCAM to predict 3-year OS included age, tumor stage, positive lymph-node status, and urine hemoglobin (Table 4). The gene discussed is ALCAM; the disease is neoplasm.